Healx will analyze proprietary Sanofi compound data using Healx’s AI-driven drug discovery platform to generate therapeutic rationale. November 13, 2024 07:00 AM Eastern Standard Time.

Sanofi SAN-0.11 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.06 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

In addition to its pharma partnership, Healx is also working on its own pipeline of medicines. This past August, the company raised $47 million in a Series C round that was co-led by R42 Group and ...

Sanofi shares fell 0.4 percent in Wall Street trading on Monday, while Blueprint’s soared more than 26 percent to $127.79 a share. Hudson shocked investors in 2023 when his research and ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, have ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company ...

Sanofi's Focus On Alzheimer's Disease The companies expect the deal to close in the third quarter. In addition to the $470 million, Vigil shareholders will receive a contingent value right, or CVR ...

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe’s Atomico and Silicon Valley-based R42.. The ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...

CAMBRIDGE, England, November 13, 2024--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI ...